share_log

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Cambyz Golestaneh(5.41%),Caissa Capital Management Ltd.(3.63%)

Avalo Therapeutics | SC 13G:超过5%持股股东披露文件-Cambyz Golestaneh(5.41%),Caissa Capital Management Ltd.(3.63%)

2022/05/17 15:45
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息